Within the pharmaceutical dissolution testing services market, In Vitro held a 60.53% share in 2025, reflecting its established role as the standard approach for routine formulation assessment, batch consistency checks, and regulatory submission support. Its leadership is maintained through the practical advantages laboratories and drug developers rely on every day: controlled test conditions, repeatable outputs, and broad applicability across development and quality workflows. These factors keep In Vitro methods at the center of service demand in the pharmaceutical dissolution testing services market, especially where dependable turnaround and standardized protocols are essential.

In Vivo Methods are emerging as the fastest-growing area of the pharmaceutical dissolution testing services market as drug developers increasingly need stronger evidence of how dissolution behavior translates into real biological performance. Growth is being underpinned by situations where in vitro results alone are not sufficient to address complex formulations, bioavailability concerns, or product-specific performance questions. Compared with conventional laboratory-based methods, In Vivo Methods gain momentum because they help bridge formulation data with physiological relevance, making them more valuable in cases that require deeper performance validation.

Dosage Form Segment Analysis: Tablets (Largest Segment) vs Capsules (Fastest-Growing Segment)

Tablets accounted for the largest share of the pharmaceutical dissolution testing services market in 2025, underpinned by their widespread use across the drug industry and the steady need for dissolution profiling throughout development, approval, and quality control. Their leading position is tied to the high volume of tablet-based products moving through standardized testing programs, where consistent release behavior and established analytical expectations keep service demand strong. In the pharmaceutical dissolution testing services market, this broad and routine testing requirement helps tablets maintain their share without relying on niche or occasional applications.

Capsules represent the fastest-growing dosage form in the pharmaceutical dissolution testing services market, driven by increasing formulation complexity and the need to evaluate release performance under conditions that are often more variable than those seen with tablets. Growth is strongest where capsule-based products require closer examination of shell behavior, fill composition, and dissolution response across different testing environments. Relative to more established tablet workflows, capsules are gaining momentum because they create a greater need for specialized dissolution assessment, which directly expands service demand.